Clinical roundtable monograph. Early death in patients with acute promyelocytic leukemia.

Martin S. Tallman, Francesco Lo-Coco, Hau C. Kwaan, Miguel A. Sanz, Steven D. Gore

Research output: Contribution to journalArticle

Abstract

With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide, acute promyelocytic leukemia (APL) has become a highly curable malignancy. Approximately 90% of patients achieve complete remission with induction, which generally includes ATRA and an anthracycline-based chemotherapy. Early death, either before treatment is initiated or during induction, has emerged as one of the most critical issues involved in the current care of patients with APL. The main cause of early death in APL is bleeding, often intracranial. It has become increasingly clear that induction therapy should be initiated in patients at the earliest time possible, even before confirmation of the diagnosis of APL has been made. In this roundtable, several experts discuss important insights into the high rate of early death observed in APL. In addition to the importance of rapid diagnosis, the pathophysiology of the coagulopathy associated with APL will be discussed, as will factors that may be predictive of early death and potential interventions to prevent this important limitation to the cure of many, if not most, patients.

Original languageEnglish (US)
Pages (from-to)1-16
Number of pages16
JournalClinical Advances in Hematology and Oncology
Volume9
Issue number2
StatePublished - Feb 2011
Externally publishedYes

Fingerprint

Acute Promyelocytic Leukemia
Tretinoin
Remission Induction
Anthracyclines
Cause of Death
Patient Care
Hemorrhage
Drug Therapy
Mortality
Therapeutics
Neoplasms

ASJC Scopus subject areas

  • Oncology
  • Hematology

Cite this

Tallman, M. S., Lo-Coco, F., Kwaan, H. C., Sanz, M. A., & Gore, S. D. (2011). Clinical roundtable monograph. Early death in patients with acute promyelocytic leukemia. Clinical Advances in Hematology and Oncology, 9(2), 1-16.

Clinical roundtable monograph. Early death in patients with acute promyelocytic leukemia. / Tallman, Martin S.; Lo-Coco, Francesco; Kwaan, Hau C.; Sanz, Miguel A.; Gore, Steven D.

In: Clinical Advances in Hematology and Oncology, Vol. 9, No. 2, 02.2011, p. 1-16.

Research output: Contribution to journalArticle

Tallman, MS, Lo-Coco, F, Kwaan, HC, Sanz, MA & Gore, SD 2011, 'Clinical roundtable monograph. Early death in patients with acute promyelocytic leukemia.', Clinical Advances in Hematology and Oncology, vol. 9, no. 2, pp. 1-16.
Tallman, Martin S. ; Lo-Coco, Francesco ; Kwaan, Hau C. ; Sanz, Miguel A. ; Gore, Steven D. / Clinical roundtable monograph. Early death in patients with acute promyelocytic leukemia. In: Clinical Advances in Hematology and Oncology. 2011 ; Vol. 9, No. 2. pp. 1-16.
@article{afd12fb908cd474b8a9a545d7bd8192d,
title = "Clinical roundtable monograph. Early death in patients with acute promyelocytic leukemia.",
abstract = "With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide, acute promyelocytic leukemia (APL) has become a highly curable malignancy. Approximately 90{\%} of patients achieve complete remission with induction, which generally includes ATRA and an anthracycline-based chemotherapy. Early death, either before treatment is initiated or during induction, has emerged as one of the most critical issues involved in the current care of patients with APL. The main cause of early death in APL is bleeding, often intracranial. It has become increasingly clear that induction therapy should be initiated in patients at the earliest time possible, even before confirmation of the diagnosis of APL has been made. In this roundtable, several experts discuss important insights into the high rate of early death observed in APL. In addition to the importance of rapid diagnosis, the pathophysiology of the coagulopathy associated with APL will be discussed, as will factors that may be predictive of early death and potential interventions to prevent this important limitation to the cure of many, if not most, patients.",
author = "Tallman, {Martin S.} and Francesco Lo-Coco and Kwaan, {Hau C.} and Sanz, {Miguel A.} and Gore, {Steven D.}",
year = "2011",
month = "2",
language = "English (US)",
volume = "9",
pages = "1--16",
journal = "Nature Clinical Practice Oncology",
issn = "1759-4774",
publisher = "Nature Publishing Group",
number = "2",

}

TY - JOUR

T1 - Clinical roundtable monograph. Early death in patients with acute promyelocytic leukemia.

AU - Tallman, Martin S.

AU - Lo-Coco, Francesco

AU - Kwaan, Hau C.

AU - Sanz, Miguel A.

AU - Gore, Steven D.

PY - 2011/2

Y1 - 2011/2

N2 - With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide, acute promyelocytic leukemia (APL) has become a highly curable malignancy. Approximately 90% of patients achieve complete remission with induction, which generally includes ATRA and an anthracycline-based chemotherapy. Early death, either before treatment is initiated or during induction, has emerged as one of the most critical issues involved in the current care of patients with APL. The main cause of early death in APL is bleeding, often intracranial. It has become increasingly clear that induction therapy should be initiated in patients at the earliest time possible, even before confirmation of the diagnosis of APL has been made. In this roundtable, several experts discuss important insights into the high rate of early death observed in APL. In addition to the importance of rapid diagnosis, the pathophysiology of the coagulopathy associated with APL will be discussed, as will factors that may be predictive of early death and potential interventions to prevent this important limitation to the cure of many, if not most, patients.

AB - With the introduction of all-trans retinoic acid (ATRA) and arsenic trioxide, acute promyelocytic leukemia (APL) has become a highly curable malignancy. Approximately 90% of patients achieve complete remission with induction, which generally includes ATRA and an anthracycline-based chemotherapy. Early death, either before treatment is initiated or during induction, has emerged as one of the most critical issues involved in the current care of patients with APL. The main cause of early death in APL is bleeding, often intracranial. It has become increasingly clear that induction therapy should be initiated in patients at the earliest time possible, even before confirmation of the diagnosis of APL has been made. In this roundtable, several experts discuss important insights into the high rate of early death observed in APL. In addition to the importance of rapid diagnosis, the pathophysiology of the coagulopathy associated with APL will be discussed, as will factors that may be predictive of early death and potential interventions to prevent this important limitation to the cure of many, if not most, patients.

UR - http://www.scopus.com/inward/record.url?scp=84861308060&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861308060&partnerID=8YFLogxK

M3 - Article

C2 - 22379665

AN - SCOPUS:84861308060

VL - 9

SP - 1

EP - 16

JO - Nature Clinical Practice Oncology

JF - Nature Clinical Practice Oncology

SN - 1759-4774

IS - 2

ER -